Vanda Pharmaceuticals Inc., of Washington, reported that combined net sales from Hetlioz (tasimelteon) and Fanapt (iloperidone) were $59.1 million in the second quarter, representing a 24% increase from $47.7 million in the first quarter and a 25% increase from $47.4 million in the second quarter of 2018.